WO2000012726A3 - Rationally designed heparinases derived from heparinase i and ii - Google Patents

Rationally designed heparinases derived from heparinase i and ii Download PDF

Info

Publication number
WO2000012726A3
WO2000012726A3 PCT/US1999/019841 US9919841W WO0012726A3 WO 2000012726 A3 WO2000012726 A3 WO 2000012726A3 US 9919841 W US9919841 W US 9919841W WO 0012726 A3 WO0012726 A3 WO 0012726A3
Authority
WO
WIPO (PCT)
Prior art keywords
heparinases
heparinase
derived
rationally designed
modified heparinases
Prior art date
Application number
PCT/US1999/019841
Other languages
French (fr)
Other versions
WO2000012726A2 (en
Inventor
Zachary Shriver
Ganesh Venkataraman
Ram Sasisekharan
Dongfang Liu
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Priority to JP2000567712A priority Critical patent/JP2003527822A/en
Priority to CA002341412A priority patent/CA2341412A1/en
Priority to EP99945315A priority patent/EP1109919A2/en
Publication of WO2000012726A2 publication Critical patent/WO2000012726A2/en
Publication of WO2000012726A3 publication Critical patent/WO2000012726A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Modified heparinases having altered binding specificity and activity are provided. Isolated nucleic acids encoding the same as well as vectors and host cells are provided. Methods for using the modified heparinases are also provided.
PCT/US1999/019841 1998-08-27 1999-08-27 Rationally designed heparinases derived from heparinase i and ii WO2000012726A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000567712A JP2003527822A (en) 1998-08-27 1999-08-27 Rationally designed heparinases from heparinases I and II
CA002341412A CA2341412A1 (en) 1998-08-27 1999-08-27 Rationally designed heparinases derived from heparinase i and ii
EP99945315A EP1109919A2 (en) 1998-08-27 1999-08-27 Rationally designed heparinases derived from heparinase i and ii

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9815398P 1998-08-27 1998-08-27
US60/098,153 1998-08-27

Publications (2)

Publication Number Publication Date
WO2000012726A2 WO2000012726A2 (en) 2000-03-09
WO2000012726A3 true WO2000012726A3 (en) 2000-06-29

Family

ID=22267548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019841 WO2000012726A2 (en) 1998-08-27 1999-08-27 Rationally designed heparinases derived from heparinase i and ii

Country Status (5)

Country Link
US (2) US7560106B2 (en)
EP (1) EP1109919A2 (en)
JP (1) JP2003527822A (en)
CA (1) CA2341412A1 (en)
WO (1) WO2000012726A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012726A2 (en) * 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
EP1190364A2 (en) * 1999-04-23 2002-03-27 Massachusetts Institute Of Technology System and method for polymer notation
US6979563B1 (en) * 1999-11-17 2005-12-27 Biomarin Enzymes, Inc. Attenuation of tumor growth, metastasis and angiogenesis
EP1266013B1 (en) 2000-03-08 2014-10-15 Massachusetts Institute Of Technology Heparinase iii and uses thereof
WO2002023190A2 (en) 2000-09-12 2002-03-21 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
CA2423469A1 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
JP4416664B2 (en) 2002-05-03 2010-02-17 マサチューセッツ・インスティテュート・オブ・テクノロジー Δ4,5 glycuronidase and use thereof
EP1575548B1 (en) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
JP4657726B2 (en) 2002-05-20 2011-03-23 マサチューセッツ インスティテュート オブ テクノロジー A novel method for sequencing using NMR
AU2003265561A1 (en) * 2002-08-15 2004-03-03 Acorda Therapeutics, Inc. Chimeric protein
JP4606712B2 (en) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
MXPA05012307A (en) 2003-05-16 2006-07-03 Acorda Therapeutics Inc Proteoglycan degrading mutants for treatment of cns.
MXPA05012305A (en) * 2003-05-16 2006-04-18 Acorda Therapeutics Inc Compositions and methods for the treatment of cns injuries.
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
WO2005087920A2 (en) 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
AU2005244933B2 (en) * 2004-05-18 2011-08-04 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20060154894A1 (en) * 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
EP1928490B8 (en) 2005-09-26 2012-10-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
US7691612B2 (en) 2005-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7767420B2 (en) * 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7691613B2 (en) 2006-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Glycosaminoglycan lyase IV and uses thereof
EP2008096A2 (en) * 2006-04-03 2008-12-31 Massachusetts Institute of Technology Glycomic patterns for the detection of disease
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
WO2008085912A1 (en) 2007-01-05 2008-07-17 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
CN111304229A (en) * 2019-12-11 2020-06-19 泉州师范学院 Heparinase gene engineering expression product and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034635A1 (en) * 1994-06-10 1995-12-21 Ibex Technologies Nucleic acid sequences and expression systems for heparinase ii and heparinase iii derived from flavobacterium heparinum

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281108A (en) 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
US4341869A (en) 1980-08-25 1982-07-27 Massachusetts Institute Of Technology Process for producing heparinase
US4443545A (en) 1980-08-25 1984-04-17 Massachusetts Institute Of Technology Process for producing heparinase
US4373023A (en) 1980-10-14 1983-02-08 Massachusetts Institute Of Technology Process for neutralizing heparin
US4396762A (en) 1981-08-24 1983-08-02 Massachusetts Institute Of Technology Heparinase derived anticoagulants
US4551296A (en) 1982-03-19 1985-11-05 Allied Corporation Producing high tenacity, high modulus crystalline article such as fiber or film
US4757056A (en) 1984-03-05 1988-07-12 Hepar Industries, Inc. Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions
DE3422518A1 (en) 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen HEPARIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF FATTY METABOLISM DISORDERS
US5106734A (en) 1986-04-30 1992-04-21 Novo Nordisk A/S Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin
US4745105A (en) 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US4942156A (en) 1986-08-20 1990-07-17 Hepar Industries, Inc. Low molecular weight heparin derivatives having improved anti-Xa specificity
US4830013A (en) 1987-01-30 1989-05-16 Minnesota Mining And Manufacturing Co. Intravascular blood parameter measurement system
FR2614026B1 (en) 1987-04-16 1992-04-17 Sanofi Sa LOW MOLECULAR WEIGHT HEPARINS WITH REGULAR STRUCTURE, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
SE8702254D0 (en) 1987-05-29 1987-05-29 Kabivitrum Ab NOVEL HEPARIN DERIVATIVES
US5169772A (en) 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
IT1234508B (en) 1988-06-10 1992-05-19 Alfa Wassermann Spa HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
GB8826448D0 (en) 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
JPH0693836B2 (en) 1988-11-25 1994-11-24 新技術事業団 Heparinase-producing microorganism belonging to the genus Bacillus, novel heparinase, and method for producing the same
CA1340966C (en) 1989-05-19 2000-04-18 Thomas R. Covey Method of protein analysis
IT1237518B (en) 1989-11-24 1993-06-08 Renato Conti SUPER-SULFATED HEPARINS
US5152784A (en) 1989-12-14 1992-10-06 Regents Of The University Of Minnesota Prosthetic devices coated with a polypeptide with type IV collagen activity
IT1245761B (en) 1991-01-30 1994-10-14 Alfa Wassermann Spa PHARMACEUTICAL FORMULATIONS CONTAINING GLYCOSAMINOGLICANS ABSORBABLE ORALLY.
JP3110064B2 (en) 1991-03-06 2000-11-20 生化学工業株式会社 Novel heparitinase, method for producing the same and bacteria producing the same
US5262325A (en) 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
JPH06507635A (en) 1991-05-02 1994-09-01 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Compositions for the prevention and/or treatment of pathological processes
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
US5453171A (en) 1992-03-10 1995-09-26 The Board Of Regents Of The University Of Michigan Heparin-selective polymeric membrane electrode
US5856928A (en) 1992-03-13 1999-01-05 Yan; Johnson F. Gene and protein representation, characterization and interpretation process
US5389539A (en) 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
FR2704861B1 (en) 1993-05-07 1995-07-28 Sanofi Elf Purified heparin fractions, process for obtaining them and pharmaceutical compositions containing them.
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
CA2176934A1 (en) 1993-11-17 1995-05-26 Ramnath Sasisekharan Method for inhibiting angiogenesis using heparinase
US6013628A (en) 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
US5607859A (en) 1994-03-28 1997-03-04 Massachusetts Institute Of Technology Methods and products for mass spectrometric molecular weight determination of polyionic analytes employing polyionic reagents
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
CA2189038A1 (en) 1994-05-06 1995-11-09 Kevin R. Holme O-desulfated heparin derivatives, methods of making and uses thereof
US5619421A (en) 1994-06-17 1997-04-08 Massachusetts Institute Of Technology Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
FR2723847A1 (en) 1994-08-29 1996-03-01 Debiopharm Sa HEPARIN - BASED ANTITHROMBOTIC AND NON - HEMORRHAGIC COMPOSITIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS.
US5687090A (en) 1994-09-01 1997-11-11 Aspen Technology, Inc. Polymer component characterization method and process simulation apparatus
ATE198979T1 (en) 1994-10-12 2001-02-15 Focal Inc TARGETED DISHES ADMINISTERED USING BIODEGRADABLE POLYMERS
US5569366A (en) 1995-01-27 1996-10-29 Beckman Instruments, Inc. Fluorescent labelled carbohydrates and their analysis
US5618917A (en) 1995-02-15 1997-04-08 Arch Development Corporation Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
US5763427A (en) 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
JP3318578B2 (en) 1995-05-26 2002-08-26 サーモディックス，インコーポレイティド Methods for promoting endothelialization and implantable products
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
US5752019A (en) 1995-12-22 1998-05-12 International Business Machines Corporation System and method for confirmationally-flexible molecular identification
US5990097A (en) 1996-07-29 1999-11-23 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
JP4335316B2 (en) 1996-09-19 2009-09-30 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Polymers containing polysaccharides such as alginate or modified alginate
US5767269A (en) 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
US5759767A (en) 1996-10-11 1998-06-02 Joseph R. Lakowicz Two-photon and multi-photon measurement of analytes in animal and human tissues and fluids
US6642360B2 (en) 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
US6190875B1 (en) 1997-09-02 2001-02-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
US5968822A (en) 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6268146B1 (en) 1998-03-13 2001-07-31 Promega Corporation Analytical methods and materials for nucleic acid detection
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
WO2000012726A2 (en) * 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US6291439B1 (en) 1998-09-02 2001-09-18 Biomarin Pharmaceuticals Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
EP1190364A2 (en) 1999-04-23 2002-03-27 Massachusetts Institute Of Technology System and method for polymer notation
EP1266013B1 (en) 2000-03-08 2014-10-15 Massachusetts Institute Of Technology Heparinase iii and uses thereof
WO2002023190A2 (en) 2000-09-12 2002-03-21 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
CA2423469A1 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
AU2002306921A1 (en) 2001-03-27 2002-10-08 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
JP4416664B2 (en) * 2002-05-03 2010-02-17 マサチューセッツ・インスティテュート・オブ・テクノロジー Δ4,5 glycuronidase and use thereof
JP4657726B2 (en) 2002-05-20 2011-03-23 マサチューセッツ インスティテュート オブ テクノロジー A novel method for sequencing using NMR
US6962699B2 (en) 2002-06-03 2005-11-08 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase B
JP4606712B2 (en) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
WO2005087920A2 (en) * 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005110438A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
CA2614068A1 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20060154894A1 (en) * 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
US20070020243A1 (en) * 2005-01-12 2007-01-25 Massachusetts Institute Of Technology Methods and compositions related to modulating the extracellular stem cell environment
KR100965692B1 (en) * 2005-02-01 2010-06-24 삼성전자주식회사 Apparatus and method for displaying the status of supplementary service of mobile terminal equipment
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
EP2008096A2 (en) * 2006-04-03 2008-12-31 Massachusetts Institute of Technology Glycomic patterns for the detection of disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034635A1 (en) * 1994-06-10 1995-12-21 Ibex Technologies Nucleic acid sequences and expression systems for heparinase ii and heparinase iii derived from flavobacterium heparinum

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SASISEKHARAN R ET AL: "HEPARINASE I FROM FLAVOBACTERIUM HEPARINUM: THE ROLE OF THE CYSTEINE RESIDUE IN CATALYSIS AS PROBED BY CHEMICAL MODIFICATION AND SITE-DIRECTED MUTAGENESIS", BIOCHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, PA, vol. 34, no. 44, pages 14441-14448, XP002026383, ISSN: 0006-2960 *
SHRIVER Z ET AL.: "Heparinase II from Flavobacterium heparinum: Role of cysteine in enzymatic activity as probed by chemical modification and site-directed mutagenesis", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 36, 4 September 1998 (1998-09-04), MD US, pages 22904 - 22912, XP002127286 *
SHRIVER Z ET AL.: "Heparinase II from flavobacterium heparinum: Role of histidine residues in enzymatic activity as probed by chemical modification and site-directed mutagenesis", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 17, 24 April 1998 (1998-04-24), MD US, pages 10160 - 10167, XP002127285 *

Also Published As

Publication number Publication date
US7560106B2 (en) 2009-07-14
US20060105430A1 (en) 2006-05-18
JP2003527822A (en) 2003-09-24
US20070148158A1 (en) 2007-06-28
WO2000012726A2 (en) 2000-03-09
EP1109919A2 (en) 2001-06-27
CA2341412A1 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
WO2000012726A3 (en) Rationally designed heparinases derived from heparinase i and ii
ZA981762B (en) Nucleic acid molecules encoding enzymes having fructosyl polymerase activity.
IL134537A0 (en) Nucleic acid encoding an april ligand or a fragment thereof, vectors and host cells containing the same and methods for the production thereof
AU3246300A (en) Polypeptides having galactose oxidase activity and nucleic acids encoding same
WO2001029222A3 (en) Polypeptides having phospholipase b activity and nucleic acids encoding same
WO2001079463A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
WO2000060060A3 (en) Polypeptides having alkaline alpha-amylase activity and nucleic acids encoding same
CA2315274A1 (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
WO2000018914A3 (en) Novel dkr polypeptides
WO2001004264A3 (en) Atherosclerosis-associated genes
WO1998021343A8 (en) Genes encoding telomerase proteins
WO2002062999A3 (en) Proteins and nucleic acids encoding same
WO1999067382A3 (en) Angiopoietin-like growth factor sequences
AU7489098A (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
WO1995034651A3 (en) Corticotropin-releasing factor2 receptors
WO2001098469A3 (en) Polypeptides having peroxidase activity and nucleic acids encoding same
WO1997027276A3 (en) Nucleic acids encoding polypeptides having absidia lipase activity
CA2361987A1 (en) Goodpasture antigen binding protein
AU2462399A (en) Cubilin protein, dna sequences encoding cubilin and uses thereof
WO2000028043A3 (en) Polypeptides having lactonohydrolase activity and nucleic acids encoding same
AU1981295A (en) Novel protein-kinase, nucleic acid sequences encoding the same and methods related thereto
AU5727099A (en) A 2,6-beta-d-fructan hydrolase enzyme and processes for using the enzyme
ZA200101737B (en) Nucleic acid molecules which code for enzymes with fructosyltransferase activity and use thereof.
WO2000041509A3 (en) Polypeptides having acid phosphatase activity and nucleic acids encoding same
AU6454398A (en) Novel rna editing enzyme

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2341412

Country of ref document: CA

Ref country code: CA

Ref document number: 2341412

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999945315

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999945315

Country of ref document: EP